Insmed Inc

Quantli Newsdesk

· 3 months ago

Avalyn Pharma raised $300 million in an upsized IPO, pricing shares at the top of its range and expanding the offering by nearly 30%. The biotech stock jumped 44% on its trading debut, reflecting renewed investor appetite for biopharma companies developing treatments for rare diseases. Novo Holdings, the investment arm of Novo Nordisk's controlling shareholder, is among the company's backers.